

CLNE0029: Clinical neuroscience of neurodegenerative diseases

[View Online](#)

-
1.
Neurology: a Queen Square textbook. (Wiley Blackwell, 2016).
 2.
McCarthy, R. A. & Warrington, E. K. Cognitive neuropsychology: a clinical introduction. (Academic Press, Inc, 1990).
 3.
Rossor, M. & Growdon, J. H. The dementias 2. (Butterworth Heinemann/Elsevier, 2007).
 4.
Hodges, J. R. Cognitive assessment for clinicians. (Oxford University Press, 2017).
 5.
Principles of neural science. (McGraw Hill Medical, 2013).
 6.
Husain, M. Oxford textbook of cognitive neurology and dementia. (Oxford University Press, 2016).
 - 7.

Alzheimer's Facts and Figures Report | Alzheimer's Association.
<https://www.alz.org/alzheimers-dementia/facts-figures>.

8.

Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Molecular Medicine* **8**, 595–608 (2016).

9.

Dubois, B. et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. *The Lancet Neurology* **13**, 614–629 (2014).

10.

Loy, C. T., Schofield, P. R., Turner, A. M. & Kwok, J. B. Genetics of dementia. *The Lancet* **383**, 828–840 (2014).

11.

Karran, E. & Hardy, J. Anti-amyloid Therapy for Alzheimer's Disease — Are We on the Right Road? *New England Journal of Medicine* **370**, 377–378 (2014).

12.

Johnson, K. A., Fox, N. C., Sperling, R. A. & Klunk, W. E. Brain Imaging in Alzheimer Disease. *Cold Spring Harbor Perspectives in Medicine* **2**, a006213–a006213 (2012).

13.

Ross, C. A. et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. *Nature Reviews Neurology* **10**, 204–216 (2014).

14.

Bates, G. P. et al. Huntington disease. *Nature Reviews Disease Primers* (2015)
doi:10.1038/nrdp.2015.5.

15.

Wild, E. J. & Tabrizi, S. J. Therapies targeting DNA and RNA in Huntington's disease. *The Lancet Neurology* **16**, 837–847 (2017).

16.

Carroll, J. B., Bates, G. P., Steffan, J., Saft, C. & Tabrizi, S. J. Treating the whole body in Huntington's disease. *The Lancet Neurology* **14**, 1135–1142 (2015).

17.

Tabrizi, S. J. et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. *The Lancet Neurology* **10**, 31–42 (2011).

18.

Tabrizi, S. J. et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. *The Lancet Neurology* **11**, 42–53 (2012).

19.

Tabrizi, S. J. et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. *The Lancet Neurology* **12**, 637–649 (2013).

20.

Jones, L., Houlden, H. & Tabrizi, S. J. DNA repair in the trinucleotide repeat disorders. *The Lancet Neurology* **16**, 88–96 (2017).

21.

Rossor, M. et al. Dementia and Cognitive Impairment. in *Neurology* (eds. Clarke, C., Howard, R., Rossor, M. & Shorvon, S.) 289–336 (John Wiley & Sons, Ltd, 2016).

doi:10.1002/9781118486160.ch8.

22.

Rossor, M. N., Fox, N. C., Mummery, C. J., Schott, J. M. & Warren, J. D. The diagnosis of young-onset dementia. *The Lancet Neurology* **9**, 793–806 (2010).

23.

Schott, J. M., Fox, N. C. & Rossor, M. N. Assessment and investigation of the cognitively impaired adult. in *Oxford Textbook of Cognitive Neurology and Dementia* (eds. Husain, M. & Schott, J. M.) 221–230 (Oxford University Press, 2016).
doi:10.1093/med/9780199655946.003.0021.

24.

Green, A. J. E. RT-QulC: a new test for sporadic CJD. *Practical Neurology* (2018)
doi:10.1136/practneurol-2018-001935.

25.

Collinge, J. Mammalian prions and their wider relevance in neurodegenerative diseases. *Nature* **539**, 217–226 (2016).

26.

Mead, S. & Rudge, P. CJD mimics and chameleons. *Practical Neurology* **17**, 113–121 (2017).

27.

Walker, Z., Possin, K. L., Boeve, B. F. & Aarsland, D. Lewy body dementias. *The Lancet* **386**, 1683–1697 (2015).

28.

Halliday, G. M., Holton, J. L., Revesz, T. & Dickson, D. W. Neuropathology underlying clinical

variability in patients with synucleinopathies. *Acta Neuropathologica* **122**, 187–204 (2011).

29.

Barker, R. A. & Williams-Gray, C. H. Review: The spectrum of clinical features seen with alpha synuclein pathology. *Neuropathology and Applied Neurobiology* **42**, 6–19 (2016).

30.

Bras, J. et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. *Human Molecular Genetics* **23**, 6139–6146 (2014).

31.

McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies. *Neurology* **89**, 88–100 (2017).

32.

Weil, R. S., Lashley, T. L., Bras, J., Schrag, A. E. & Schott, J. M. Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies. *F1000Research* **6**, (2017).

33.

Woollacott, I. O. C. & Rohrer, J. D. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. *Journal of Neurochemistry* **138**, 6–31 (2016).

34.

Gordon, E., Rohrer, J. D. & Fox, N. C. Advances in neuroimaging in frontotemporal dementia. *Journal of Neurochemistry* **138**, 193–210 (2016).

35.

Ahmed, R. M. et al. Neuronal network disintegration: common pathways linking neurodegenerative diseases. *Journal of Neurology, Neurosurgery & Psychiatry* **87**, 1234–1241 (2016).

36.

Fletcher, P. D. & Warren, J. D. Semantic Dementia: a specific network-opathy. *Journal of Molecular Neuroscience* **45**, 629–636 (2011).

37.

Goll, J. C. et al. Non-verbal sound processing in the primary progressive aphasia. *Brain* **133**, 272–285 (2010).

38.

Goll, J. C., Ridgway, G. R., Crutch, S. J., Theunissen, F. E. & Warren, J. D. Nonverbal sound processing in semantic dementia: A functional MRI study. *NeuroImage* **61**, 170–180 (2012).

39.

Gorno-Tempini, M. L. et al. Classification of primary progressive aphasia and its variants. *Neurology* **76**, 1006–1014 (2011).

40.

Grossman, M. The non-fluent/agrammatic variant of primary progressive aphasia. *The Lancet Neurology* **11**, 545–555 (2012).

41.

Leyton, C. E. et al. Is the logopenic-variant of primary progressive aphasia a unitary disorder? *Cortex* **67**, 122–133 (2015).

42.

Marshall, C. R. et al. Primary progressive aphasia: a clinical approach. *Journal of Neurology* **265**, 1474–1490 (2018).

43.

Rohrer, J. D. et al. Word-finding difficulty: a clinical analysis of the progressive aphasias. *Brain* **131**, 8–38 (2007).

44.

Rohrer, J. D. et al. Progressive logopenic/phonological aphasia: Erosion of the language network. *NeuroImage* **49**, 984–993 (2010).

45.

Rohrer, J. D., Rossor, M. N. & Warren, J. D. Syndromes of nonfluent primary progressive aphasia: A clinical and neurolinguistic analysis. *Neurology* **75**, 603–610 (2010).

46.

Rohrer, J. D., Sauter, D., Scott, S., Rossor, M. N. & Warren, J. D. Receptive prosody in nonfluent primary progressive aphasias. *Cortex* **48**, 308–316 (2012).

47.

Warren, J. D., Rohrer, J. D. & Rossor, M. N. Frontotemporal dementia. *BMJ* **347**, f4827–f4827 (2013).

48.

Lynch, D. S. et al. Clinical and genetic characterization of leukoencephalopathies in adults. *Brain* **140**, 1204–1211 (2017).

49.

Inherited metabolic disease in adults: a clinical guide. (Oxford University Press, 2016).

50.

Devenney, E., Vucic, S., Hodges, J. R. & Kiernan, M. C. Motor neuron disease-frontotemporal dementia: a clinical continuum. *Expert Review of Neurotherapeutics* **15**, 509–522 (2015).

51.

Strong, M. J. et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration* **18**, 153–174 (2017).

52.

Iranzo, A. et al. Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients. *PLoS ONE* **9**, (2014).

53.

Kielb, S. A., Ancoli-Israel, S., Rebok, G. W. & Spira, A. P. Cognition in Obstructive Sleep Apnea-Hypopnea Syndrome (OSAS): Current Clinical Knowledge and the Impact of Treatment. *NeuroMolecular Medicine* **14**, 180–193 (2012).

54.

Mander, B. A., Winer, J. R., Jagust, W. J. & Walker, M. P. Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease? *Trends in Neurosciences* **39**, 552–566 (2016).

55.

McCarter, S. J., St. Louis, E. K. & Boeve, B. F. Sleep Disturbances in Frontotemporal Dementia. *Current Neurology and Neuroscience Reports* **16**, (2016).

56.

Ooms, S. & Ju, Y.-E. Treatment of Sleep Disorders in Dementia. *Current Treatment Options*

in Neurology **18**, (2016).

57.

Hardy, C. J. D. et al. Hearing and dementia. Journal of Neurology **263**, 2339–2354 (2016).

58.

Livingston, G. et al. Dementia prevention, intervention, and care. The Lancet **390**, 2673–2734 (2017).

59.

Goll, J. C., Crutch, S. J. & Warren, J. D. Central auditory disorders: toward a neuropsychology of auditory objects. Current Opinion in Neurology **23**, 617–627 (2010).

60.

Husain, M. Oxford textbook of cognitive neurology and dementia. (Oxford University Press, 2016).

61.

Blennow, K., Hardy, J. & Zetterberg, H. The Neuropathology and Neurobiology of Traumatic Brain Injury. Neuron **76**, 886–899 (2012).

62.

Smith, D. H., Johnson, V. E. & Stewart, W. Chronic neuropathologies of single and repetitive TBI: substrates of dementia? Nature Reviews Neurology **9**, 211–221 (2013).

63.

McKee, A. C. et al. The spectrum of disease in chronic traumatic encephalopathy. Brain **136**, 43–64 (2013).

64.

Fleminger, S. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. *Journal of Neurology, Neurosurgery & Psychiatry* **74**, 857–862 (2003).

65.

Scott, G. et al. Amyloid pathology and axonal injury after brain trauma. *Neurology* **86**, 821–828 (2016).

66.

Hereditary and sporadic beta-amyloidoses.
<https://www.bioscience.org/2013/v18/af/4173/fulltext.htm>.

67.

Johnson, G. V. W. Tau phosphorylation in neuronal cell function and dysfunction. *Journal of Cell Science* **117**, 5721–5729 (2004).

68.

Revesz, T. et al. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. *Acta Neuropathologica* **118**, 115–130 (2009).

69.

Montine, T. J. et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathologica* **123**, 1–11 (2012).

70.

Thal, D. R. Neurodegeneration in Normal Brain Aging and Disease. *Science of Aging Knowledge Environment* **2004**, pe26–pe26 (2004).

71.

Braak, H. & Braak, E. Staging of alzheimer's disease-related neurofibrillary changes. *Neurobiology of Aging* **16**, 271–278 (1995).

72.

Mirra, S. S. et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* **41**, 479–479 (1991).

73.

Montine, T. J. et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathologica* **123**, 1–11 (2012).

74.

Dobson, R. & Alvares, D. The difficulties with vitamin B. *Practical Neurology* **16**, 308–311 (2016).

75.

Jonathan Carr. Neurosyphilis. *Practical Neurology* **3**, 328–341 (2003).

76.

Graus, F. et al. A clinical approach to diagnosis of autoimmune encephalitis. *The Lancet Neurology* **15**, 391–404 (2016).

77.

Salvarani, C., Brown, R. D. & Hunder, G. G. Adult primary central nervous system vasculitis. *The Lancet* **380**, 767–777 (2012).

78.

Halperin, J. J. et al. Practice guideline: Idiopathic normal pressure hydrocephalus: Response to shunting and predictors of response. *Neurology* **85**, 2063–2071 (2015).

79.

Arash Asher. The effect of cancer treatment on cognitive function. undefined.

80.

Graus, F. et al. A clinical approach to diagnosis of autoimmune encephalitis. *The Lancet Neurology* **15**, 391–404 (2016).

81.

Cognitive Impairment Associated with Cancer: A Brief Review. *Innovations in Clinical Neuroscience* **15**, (2018).

82.

Haddow, L. J., Cartledge, J. D. & Manji, H. HIV and the brain: from AIDS to old age. *Clinical Medicine* **13**, s24–s28 (2013).

83.

Nightingale, S., Michael, B. D., Defres, S., Benjamin, L. A. & Solomon, T. Test them all; an easily diagnosed and readily treatable cause of dementia with life-threatening consequences if missed. *Practical Neurology* **13**, 354–356 (2013).

84.

HIV in the United Kingdom 2016 infographic.
<https://www.gov.uk/government/publications/hiv-in-the-united-kingdom>.

85.

Itzhaki, R. F. et al. Microbes and Alzheimer's Disease. *Journal of Alzheimer's Disease* **51**, 979–984 (2016).

86.

Nightingale, S. et al. Controversies in HIV-associated neurocognitive disorders. *The Lancet Neurology* **13**, 1139–1151 (2014).

87.

Richard W. Price and Bruce J. Brew. The AIDS Dementia Complex. *The Journal of Infectious Diseases* **158**, (1988).

88.

UK National Guidelines for HIV Testing 2008. <https://www.bhiva.org/HIV-testing-guidelines>.

89.

Zhou, L., Miranda-Saksena, M. & Saksena, N. K. Viruses and neurodegeneration. *Virology Journal* **10**, (2013).

90.

De Chiara, G. et al. Infectious Agents and Neurodegeneration. *Molecular Neurobiology* **46**, 614–638 (2012).

91.

Wendorf, K. A. et al. Subacute Sclerosing Panencephalitis: The Devastating Measles Complication That Might Be More Common Than Previously Estimated. *Clinical Infectious Diseases* **65**, 226–232 (2017).

92.

Ghanem, K. G. REVIEW: Neurosyphilis: A Historical Perspective and Review. *CNS*

Neuroscience & Therapeutics **16**, e157–e168 (2010).

93.

Somasundaram, O. Neuro syphilis: Portrayals by Sir Arthur Conan Doyle. Indian Journal of Psychiatry **51**, (2009).

94.

Hachinski, V. et al. National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards. Stroke **37**, 2220–2241 (2006).

95.

Gorelick, P. B. et al. Vascular Contributions to Cognitive Impairment and Dementia. Stroke **42**, 2672–2713 (2011).

96.

Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. The Lancet **357**, 169–175 (2001).

97.

Leys, D., Hénon, H., Mackowiak-Cordoliani, M.-A. & Pasquier, F. Poststroke dementia. The Lancet Neurology **4**, 752–759 (2005).

98.

O'Brien, J. T. & Thomas, A. Vascular dementia. The Lancet **386**, 1698–1706 (2015).